Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements

References

• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 [2018];73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2019;13:100–108.
   PubMed Web of Science ®Google Scholar
• Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118(1):138–145.
   PubMed Web of Science ®Google Scholar
• Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource utilization: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.
   PubMed Web of Science ®Google Scholar
• Toth PP, Philip S, Hull M, et al. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin Proc. 2019;94(9):1670–1680.
   PubMed Web of Science ®Google Scholar
• Aberra T, Peterson ED, Pagidipati NJ, et al. The association between triglycerides and incident cardiovascular disease: what is “optimal”? J Clin Lipidol. 2020;14(4):438–447.e3.
   PubMedGoogle Scholar
• The AIM-HIGH Investigators, Boden WE, Probstfield JL. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–2280.
   PubMed Web of Science ®Google Scholar
• Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized controlled trial. Circulation. 2020;143(6):528–539.
   PubMedGoogle Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–1245.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–e495. 2nd
   PubMed Web of Science ®Google Scholar
• Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the aim-HIGH trial (Atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013;62(17):1580–1584.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus [supplementary online data]. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447–455.
   PubMedGoogle Scholar
• Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–2159.
   PubMed Web of Science ®Google Scholar
• ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–318.
   PubMed Web of Science ®Google Scholar
• Iqbal T, Miller M. A fishy topic: VITAL, REDUCE-IT, STRENGTH, and beyond: putting omega 3 fatty acids into practice in 2021. Curr Cardiol Rep. 2021;23(8):111.
   PubMedGoogle Scholar
• Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017 Mar.
   Google Scholar
• Bhatt DL, Steg G, and Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia N Engl J Med 2019 380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Pearson GJ, Thanassoulis G, Anderson TJ, et al., Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2021;37(8):1129–1150.
   PubMed Web of Science ®Google Scholar
• Taha H, Badran HM, Kandil H, et al. Egyptian practical guidance in lipid management 2020. Egypt Heart J. 2021;73(1):17.
   PubMedGoogle Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020 [2019];41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S125–S150.
   PubMedGoogle Scholar
• Orringer CE, Jacobson TA, Maki KC. National lipid association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860–872.
   PubMed Web of Science ®Google Scholar
• Vascepa [package insert]. Bridgewater, NJ: Amarin Pharma Inc.; 2019 Dec.
   Google Scholar
• Vazkepa [summary of product characteristics]. Dublin, Ireland: Amarin Pharmaceuticals Ireland; 2021 Apr.
   Google Scholar
• Vascepa [product monograph]. Etobicoke. ON, Canada: HLS Therapeutics; 2019 Dec.
   Google Scholar
• Vazkepa [summary of product characteristics]: medicines & Healthcare products regulatory agency; 2021. Available from: https://mhraproducts4853.blob.core.windows.net/docs/a54815846b280ee190877004beb2ed5049262ee8. Accessed 2022 Jun 26
   Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200(1):135–140.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Abstract 57: reduction in ischemic stroke with icosapent ethyl - insights from REDUCE-IT. Stroke. 2021;52(suppl Suppl_1):A57.
   PubMedGoogle Scholar
• Bhatt DL, Steg PG, Miller M, et al. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74(8):1159–1161.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Miller M, Steg G, et al. editors EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl-intervention trial [oral presentation]. Chicago, IL: Annual Scientific Session of the American College of Cardiology; Mar 28-30 2020.
   Google Scholar
• Olshansky B, Bhatt DL, Miller M, et al. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e61–e63.
   PubMedGoogle Scholar
• Peterson BE, Bhatt DL, Steg PG, et al. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses. Circulation. 2021;143(1):33–44.
   PubMedGoogle Scholar
• Bhatt DL, Brinton EA, Miller M, et al. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract]. Diabetes. 2020;69(suppl 1):4–LB.
   Google Scholar
• Majithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144(22):1750–1759.
   PubMedGoogle Scholar
• Miller M. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial. Future Cardiol. 2019;15(6):391–394.
   PubMedGoogle Scholar
• Trivedi K, Le V, Nelson JR. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgrad Med. 2021;133(1):28–41.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Budoff MJ, Wani OR, et al., EPA’s pleiotropic mechanisms of action: a narrative review. Postgrad Med. 2021;133(6):651–664.
   PubMedGoogle Scholar
• Gryglewski RJ, Salmon JA, Ubatuba FB, et al. Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins. 1979;18(3):453–478.
   PubMed Web of Science ®Google Scholar
• Li XL, Steiner M. Fish oil: a potent inhibitor of platelet adhesiveness. Blood. 1990;76(5):938–945.
   PubMed Web of Science ®Google Scholar
• Kramer HJ, Stevens J, Grimminger F, et al. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52(8):1211–1217.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978;2(8081):117–119.
   PubMed Web of Science ®Google Scholar
• Yamada H, Yoshida M, Nakano Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2008;28(12):2173–2179.
   PubMed Web of Science ®Google Scholar
• Satoh-Asahara N, Shimatsu A, Sasaki Y, et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care. 2012;35(12):2631–2639.
   PubMed Web of Science ®Google Scholar
• Jaudszus A, Gruen M, Watzl B, et al. Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells. J Lipid Res. 2013;54(4):923–935.
   PubMed Web of Science ®Google Scholar
• Kawashima A, Harada T, Imada K, et al. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids. 2008;79(1–2):59–65.
   PubMed Web of Science ®Google Scholar
• Allam-Ndoul B, Guenard F, Barbier O, et al. Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages. Lipids Health Dis. 2016;15:69.
   PubMed Web of Science ®Google Scholar
• Albracht-Schulte K, Gonzalez S, Jackson A, et al. Eicosapentaenoic acid improves hepatic metabolism and reduces inflammation independent of obesity in high-fat-fed mice and in HepG2 cells. Nutrients. 2019;11(3):599.
   PubMed Web of Science ®Google Scholar
• Mo Z, Tang C, Li H, et al. Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation. Life Sci. 2020;242:117133.
   PubMed Web of Science ®Google Scholar
• Miller M, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study). Am J Cardiol. 2019;124(5):696–701.
   PubMed Web of Science ®Google Scholar
• Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114–119.
   PubMed Web of Science ®Google Scholar
• Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12(1):100.
   PubMed Web of Science ®Google Scholar
• Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178(6):3912–3917.
   PubMed Web of Science ®Google Scholar
• Oh SF, Dona M, Fredman G, et al. Resolvin E2 formation and impact in inflammation resolution. J Immunol. 2012;188(9):4527–4534.
   PubMed Web of Science ®Google Scholar
• Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem. 2012;287(13):10525–10534.
   PubMed Web of Science ®Google Scholar
• Golzari MH, Hosseini S, Koohdani F, et al. The Effect of Eicosapentaenoic Acid on the Serum Levels and Enzymatic Activity of Paraoxonase 1 in the Patients With Type 2 Diabetes Mellitus. Acta Med Iran. 2017;55(8):486–495.
   PubMedGoogle Scholar
• Golzari MH, Javanbakht MH, Ghaedi E, et al. Effect of eicosapentaenoic acid supplementation on paraoxonase 2 gene expression in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial. Clin Nutr Res. 2019;8(1):17–27.
   PubMedGoogle Scholar
• Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68(1):33–40.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335–338.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2020;1862(7):183254.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Kawashima K, Sawada T, et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun. 1997;232(2):487–491.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Takemoto Y, Yoshikawa J, et al. Increase in EPA/AA ratio predicts improvement in endothelial function in purified eicosapentaenoic acid-treated patients [abstract P6205]. Eur Heart J. 2019;40(suppl 1):3816.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Shimabukuro M, Higa N, et al. Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol Res Pract. 2012;2012:754181.
   PubMedGoogle Scholar
• Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59(4):297–304.
   PubMed Web of Science ®Google Scholar
• Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28(1):53–59.
   PubMed Web of Science ®Google Scholar
• Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231–1237.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2018;82(2):596–601.
   PubMed Web of Science ®Google Scholar
• Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27(9):1918–1925.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925–3932.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
   PubMed Web of Science ®Google Scholar
• Xiao YF, Gomez AM, Morgan JP, et al. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A. 1997;94(8):4182–4187.
   PubMed Web of Science ®Google Scholar
• Xiao YF, Ke Q, Wang SY, et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A. 2001;98(6):3606–3611.
   PubMed Web of Science ®Google Scholar
• Den Ruijter HM, Berecki G, Verkerk AO, et al. Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure. Circulation. 2008;117(4):536–544.
   PubMed Web of Science ®Google Scholar
• Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J Suppl. 2001;3(suppl D):D98–D105.
   Google Scholar
• Lee KR, Midgette Y, Shah R. Fish oil derived omega 3 fatty acids suppress adipose NLRP3 inflammasome signaling in human obesity. J Endocr Soc. 2019;3(3):504–515.
   PubMed Web of Science ®Google Scholar
• Domei T, Amemiya K, Enomoto S, et al. Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy [abstract P689]. Eur Heart J. 2013;34(suppl 1):137.
   PubMed Web of Science ®Google Scholar
• Shintani Y, Kawasaki T. The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography [abstract]. J Am Coll Cardiol. 2012;59(13):E1731.
   PubMed Web of Science ®Google Scholar
• Wakita Y, Wakida Y, Itou T, et al. High-purity-eicosapentaenoic-acid in addition to a strong statin makes regression of coronary plaque in patients with angina-pectoris and impaired glucose tolerance [abstract]. Circ J. 2013;77(suppl 1):I–2678.
   Google Scholar
• Katoh A, Ikeda H. Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese]. Ther Res. 2011;32(6):863–868.
   Google Scholar
• Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191(1):162–167.
   PubMed Web of Science ®Google Scholar
• Maeda K. Effect of highly purified eicosapentaenoic acid (EPA) for patients with multiple artery atherosclerotic risk factors and clinical usefulness of the ratio of serum EPA to arachidonic acid (AA) as the indicator of therapy effect of atherosclerosis [in Japanese]. Ther Res. 2014;35(2):177–182.
   Google Scholar
• Uehara H, Miyagi N, Shimajiri M, et al. The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495]. Eur Heart J. 2013;34(suppl 1):1011.
   Google Scholar
• Yamano T, Kubo T, Shiono Y, et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J Atheroscler Thromb. 2015;22(1):52–61.
   PubMed Web of Science ®Google Scholar
• Tokgozoglu L, Catapano AL. Can EPA evaporate plaques? Eur Heart J. 2020;41(40):3933–3935.
   PubMedGoogle Scholar
• Ando K, Watanabe T, Daidoji H, et al. Abstract 12007: combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial. Circulation. 2015;132(suppl_3):A12007.
   Google Scholar
• Alfaddagh A, Elajami TK, Ashfaque H, et al. Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. J Am Heart Assoc. 2017;6(12).
   Google Scholar
• Nakao K, Noguchi T, Miura H, et al. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected using non-contrast T1-weighted imaging: a randomized trial. SSRN. 2022 Jan 4; Online Ahead of Print. DOI:10.2139/ssrn.4000233
   Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF, Shrivastava S, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858(12):3131–3140.
   PubMed Web of Science ®Google Scholar
• Mason RP. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(2):1–11.
   PubMedGoogle Scholar
• Sato T, Horikawa M, Takei S, et al. Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2019;39(9):1802–1816.
   PubMed Web of Science ®Google Scholar
• Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Anderson JE, Bakris GL, et al. DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022;36(2):108101.
   PubMedGoogle Scholar
• Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722–e759.
   PubMedGoogle Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032.
   PubMed Web of Science ®Google Scholar
• Cheeley MK, Saseen JJ, and Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;S1933-2874(22):1–15.
   Google Scholar
• Precoma D, De Oliveira JM, Simao A, et al. Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology—2019. Arq Bras Cardiol. 2019;113(4):787–891.
   PubMed Web of Science ®Google Scholar
• Vargas-Uricoechea H, Ruiz AJ, Gómez EA, et al. Recommendations of the expert panel on pathophysiology, diagnosis and treatment of dyslipidemias in the adult population. Colombian association of endocrinology, diabetes and metabolism and Colombian society of cardiology and cardiovascular surgery. Revista Colombiana de Endocrinología Diabetes Metabolismo. 2020;7(Suppl 1):1–38.
   Google Scholar
• Chinese expert consensus on secondary prevention after coronary artery bypass surgery (2020). Chin J Thorac Cardiovasc Surg. 2021;37(4):193–203.
   Google Scholar
• Gladstone DJ, Lindsay MP, Douketis J, et al. Canadian stroke best practice recommendations: secondary prevention of stroke update 2020. Can J Neurol Sci. 2022;49(3):315–337.
   PubMedGoogle Scholar
• Saudi Diabetes Clinical Practice Guidelines (SDCPG): Saudi National Diabetes Center; 2021 [cited 2021 Sept 24]. Available from: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Saudi-Diabetes-Clinical-Practice-Guidelines.pdf. Accessed 2022 Jun 26
   Google Scholar
• Szymański FM, Mickiewicz A, Dzida G, et al. Management of dyslipidemia in Poland. Interdisciplinary expert position statement endorsed by the Polish Cardiac Society Working Group on cardiovascular pharmacotherapy—the fourth declaration of Sopot. Cardiol J. 2022;29(1):1–26.
   PubMedGoogle Scholar
• Arrieta F, Pedro-Botet J, Iglesias P, et al. Diabetes mellitus and cardiovascular risk: an update of the recommendations of the diabetes and cardiovascular disease working group of the Spanish society of diabetes (SED, 2021). Clin Investig Arterioscler. 2022;34(1):36–55.
   PubMedGoogle Scholar
• Alsayed N, Almahmeed W, Alnouri F, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis. 2021;343:28–50.
   PubMedGoogle Scholar
• Miyamoto S, Ogasawara K, Kuroda S, et al. Japan stroke society guideline 2021 for the treatment of stroke. Int J Stroke 2022 Apr 20;174749302210903. Online Ahead of Print. 10.1177/17474930221090347
   Google Scholar
• Abramson BL, Al-Omran M, Anand SS, et al. Canadian cardiovascular society 2022 guidelines for peripheral arterial disease. Can J Cardiol. 2022;38(5):560–587.
   PubMedGoogle Scholar
• Huang PH, Lu YW, Tsai YL, et al. Taiwan lipid guidelines for primary prevention. J Formos Med Assoc. 2022;S0929-6646(22):215–217.
   Google Scholar
• American Diabetes Association. Living standards of medical care in diabetes Arlington County, VA: American Diabetes Association; 2019. Available from: https://care.diabetesjournals.org/living-standards#2018. Accessed 2022 Jun 26
   Google Scholar
• Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673–e691.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141(19):e779–e806.
   PubMed Web of Science ®Google Scholar
• AACE/ACE management of dyslipidemia and prevention of cardiovascular disease algorithm: American association of clinical Endocrinologists; 2020. Available from: https://pro.aace.com/pdfs/lipids/CS-2020-0490-slides.pdf. Accessed 2022 Jun 26
   Google Scholar
• Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract. 2020;26(10):1196–1224.
   PubMed Web of Science ®Google Scholar
• Newman CB, Blaha MJ, and Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020;105(12):3613–3682.
   Google Scholar
• Draznin B, Aroda VR, Bakris G, et al. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S144–S174.
   PubMedGoogle Scholar
• Virani SS, Morris PB, Agarwala A, et al., ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;78(9):960–993.
   PubMedGoogle Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020 [2019];41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 [2020];42(14):1289–1367.
   PubMed Web of Science ®Google Scholar
• Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European atherosclerosis society task force. Atherosclerosis. 2021;325:99–109.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
   PubMed Web of Science ®Google Scholar
• Omega-3 acid ethyl esters - containing medicinal products for oral in use in secondary prevention after myocardial infarction: European Medicines Agency; 2020. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/omega-3-acid-ethyl-esters-containing-medicinal-products-oral-use-secondary-prevention-after. Accessed 2022 Jun 26
   Google Scholar
• Anderson TJ, Grégoire J, Pearson GJ, et al. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282.
   PubMed Web of Science ®Google Scholar
• Amarin Reports First Quarter 2022 Financial results and provides business update [press release]: Amarin Corporation. Available from: https://investor.amarincorp.com/news-releases/news-release-details/amarin-reports-first-quarter-2022-financial-results-and-provides. Accessed 2022 Jun 26
   Google Scholar
• Kimura K, Kimura T, Ishihara M, et al., JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83(5):1085–1196.
   PubMedGoogle Scholar
• Final appraisal document: icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides: National Institute for Health and Care Excellence; 2022. Available from: https://www.nice.org.uk/guidance/gid-ta10736/documents/final-appraisal-determination-document. Accessed 2022 Jun 26
   Google Scholar
• O’Malley PG, Arnold MJ, Kelley C, et al. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. Department of veterans affairs and U.S. Department of defense clinical practice guideline. Ann Intern Med. 2020;173(10):822–829.
   PubMedGoogle Scholar
• Chinese guideline on the primary prevention of cardiovascular diseases. Chinese J Cardiol. 2020; 48(12): 1000–1038.
   Google Scholar
• Sun YH, Chen K, Chen X, et al. Expert consensus on the management of diabetic patients with cardiovascular diseases. Chinese J Intern Med. 2021;60(5):421–437.
   PubMedGoogle Scholar
• Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826–1833.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubin S, Rosselló X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol. 2021;77(24):3031–3041.
   PubMedGoogle Scholar
• Lawler PR, Kotrri G, Koh M, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020;41(1):86–94.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267–2275.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyderidemia management. J Am Coll Cardiol. 2018;72(3):330–343.
   PubMed Web of Science ®Google Scholar
• Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2021;17(1):155–174.
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–2026.
   PubMed Web of Science ®Google Scholar
• The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors: the risk and prevention study collaborative group. N Engl J Med. 2013;368:1800–1808.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70(6):537–544.
   PubMed Web of Science ®Google Scholar
• Synnott PG, McQueen RB, Ollendorf DA, et al. The effectiveness and value of rivaroxaban and icosapent ethyl as additive therapies for cardiovascular disease. J Manag Care Spec Pharm. 2020;26(6):782–785.
   PubMedGoogle Scholar
• Ademi Z, Ofori-Asenso R, Zomer E, et al. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prevent Cardiol. 2021;28(8):897–904.
   PubMedGoogle Scholar
• Lachaine J, Charron JN, Gregoire JC, et al. Cost-effectiveness of icosapent ethyl (IPE) for the reduction of the risk of ischemic cardiovascular events in Canada [abstract PCV55]. Value Health. 2020;23(suppl 3):S496.
   Google Scholar
• Arbel R, Aboalhasan E, Hammerman A, et al. Icosapent ethyl for primary versus secondary prevention of major adverse cardiovascular events in hypertriglyceridemia-value for money analysis. Am J Med. 2021;134(7):e415–e419.
   PubMedGoogle Scholar